… median survival, 31% of patients treated with erlotinib in this study were alive at 1 year versus
22… PFS for the gefitinib-treated patient group compared to carboplatin/paclitaxel in first-line …

… In the current study, we analyzed the treatment response and … study, patients treated
with gefitinib had a significantly better ORR and longer PFS than those treated with erlotinib…

… this study is to examine the efficacy of erlotinib and gefitinib … to cetuximab, erlotinib and
gefitinib treatment resulted in … the efficacy of erlotinib or gefitinib treatment was significantly …

… The four patients enrolled when gefitinib was the EGFR inhibitor … Thus, although this study
endured slow patient accrual … treated with erlotinib and fulvestrant as compared to erlotinib …

… In this study, we compare two TKIs, erlotinib and gefitinib (10), based on their PKPD
properties (11). Both compounds are orally administered to treat epidermoid cancers with high …

… treatment of non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations.
Using a cohort of unselected patients treated with erlotinib, … mutations (erlotinib, gefitinib, and …

… for EGFR-TKI treatment of elderly patients is also limited. Therefore, this study aimed to
describe the effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly …

… in patients who received a 3rd-G EGFR-TKI following discontinuation of study treatment was
not … we conducted in this study. Our results showed that treatment with osimertinib following …

… Based on this study gefitinib was approved for the first-line treatment of the patients with
non… of patients with EGFR-mutated stage IV NSCLC the TKIs erlotinib, gefitinib, afatinib, and …

… aims of this study are to evaluate resistance mechanisms of afatinib compared with other
TKIs and analyze the performance of repeat biopsy which is critical for subsequent treatment. …